• Recently, an open-labeled, parallel arm, phase 2 RCT was conducted to determine the effectiveness and optimal dose of the ganaplacide and lumefantrine combination in treating uncomplicated malaria.

• This multicentric trial had one of its centers in India and was done to combat rising antimalarial resistance.

• The study was done in 2 parts, as follows:

      1. Part A: The optimal combination dose was tested among adolescents and adults aged    >12 years.

      2. Part B: The optimal dose calculated from Part A was tested among children <12 years.

• In both parts, the control arm received combination therapy containing artemether and lumefantrine.

• A total of 1220 patients were screened, and 337 and 175 participated in parts A and B, respectively.

• The study concluded that the combination was effective and well tolerated by all age groups.

• The optimal combination dose consisted of ganaplacide 400mg plus lumefantrine-SDF 960mg once daily for three days.

• However, further trials are required before the drug is accepted as a standard treatment regimen.

Click here to read more.